Research Topics
| J HirshSummaryAffiliation: McMaster University Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyJack Hirsh
Henderson Research Centre, 711 Concession St, Hamilton, ON L8V 1C3, Canada
Chest 126:188S-203S. 2004..The synthetic pentasaccharide fondaparinux is a promising new antithrombotic agent for the prevention and treatment of venous thromboembolism...- How we diagnose and treat deep vein thrombosisJack Hirsh
Henderson Research Centre, and the Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Blood 99:3102-10. 2002..Several new anticoagulants with theoretical advantages over existing agents are undergoing evaluation in phase 3 studies in patients with venous thromboembolism... - Advances and contemporary issues in prophylaxis for deep vein thrombosisJack Hirsh
McMaster University, Hamilton, Ontario, Canada
Chest 124:347S-348S. 2003 - New anticoagulantsJ Hirsh
Hamilton Civic Hospitals Research Centre and Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
Am Heart J 142:S3-8. 2001..Heparin and coumarins have been in clinical use for more than 50 years. Low-molecular-weight heparins (including a heparinoid), developed 25 years ago, have been used clinically for more than a decade... - Treatment of heparin-induced thrombocytopenia: a critical reviewJack Hirsh
Henderson Research Centre, Henderson Hospital, and the Department of Medicine, McMaster University, Hamilton, Ontario
Arch Intern Med 164:361-9. 2004.... - New anticoagulantsJack Hirsh
Henderson Research Center, and McMaster University, Hamilton, Ontario, Canada
Blood 105:453-63. 2005..Large phase 3 trials evaluating ximelagatran for the secondary prevention of venous thromboembolism and prevention of cardioembolic events in patients with atrial fibrillation have been completed... - Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspectiveJ Hirsh
Hamilton Civic Hospitals Research Centre, Henderson Division, 711 Concession Street, Hamilton, Ontario L8V 1C3, Canada
Ann Intern Med 134:409-17. 2001..The studies are discussed from a historical perspective, and an attempt is made to analyze both the thought processes that prompted their design and the reasons why they changed practice... - Laboratory monitoring of low-molecular-weight heparin therapyJ Hirsh
Hamilton Civic Hospital Research Center, Hamilton, Ontario, Canada
J Thromb Haemost 2:1003. 2004 - Risk of thrombosis with lenalidomide and its prevention with aspirinJack Hirsh
Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada
Chest 131:275-7. 2007..There is, therefore, a critical need to incorporate a randomized comparison of aspirin with an anticoagulant in future trials evaluating lenalidomide in multiple myeloma... - Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Jack Hirsh
Henderson Research Centre, Hamilton Civic Hospitals, 711 Concession Street, Hamilton, Ontario, Canada
Chest 133:141S-159S. 2008..Three parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in HIT patients... - Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studiesJack Hirsh
The Henderson Research Centre, Hamilton, Ontario, Canada
Arch Intern Med 164:2106-10. 2004..High-risk groups in the CAPRIE and CURE studies would be expected to derive enhanced benefit from treatment with clopidogrel over that achieved by ASA... - Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trialJ A M Anderson
Division of Hematology, and Cardiology, Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
J Thromb Haemost 8:243-9. 2010..The mechanism of lower bleeding and improved efficacy with fondaparinux is uncertain... - Beyond unfractionated heparin and warfarin: current and future advancesJack Hirsh
Henderson Research Centre, Hamilton Health Sciences Corporatin, Ontario, Canada
Circulation 116:552-60. 2007 - Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trialM A Crowther
Department of Medicine, McMaster University, Hamilton, ON, Canada
Lancet 356:1551-3. 2000..We aimed to assess whether treatment with vitamin K is safe and more effective than placebo in rapidly lowering the international normalised ratio (INR) into the therapeutic range in over anticoagulated patients receiving warfarin... - Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin timesS S Anand
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Arch Intern Med 159:2029-32. 1999..The presence of an association between early subtherapeutic activated partial thromboplastin times (aPTTs) and recurrent venous thromboembolism (VTE) remains controversial... - Vasoflux, a new anticoagulant with a novel mechanism of actionJ I Weitz
Hamilton Civic Hospitals Reseach Centre, Hamilton, Ontario, Canada
Circulation 99:682-9. 1999..Heparin does not inactivate fibrin-bound thrombin, whereas hirudin fails to block thrombin generation. In contrast, Vasoflux is a novel anticoagulant that inactivates fibrin-bound thrombin and attenuates factor Xa generation... - Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR StudyJ A Cairns
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Circulation 94:1553-60. 1996..Low-molecular-weight heparin (LMWH) has reduced cellular proliferation and restenosis in several experimental systems... - Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimerP S Wells
Department of Medicine, University of Ottawa, Ontario, Canada
Thromb Haemost 83:416-20. 2000..The combination of a score < or =4.0 by our simple clinical prediction rule and a negative SimpliRED D-Dimer result may safely exclude PE in a large proportion of patients with suspected PE... - Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparinSonia S Anand
McMaster Clinic Population Health Section, 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada
Circulation 107:2884-8. 2003..Therefore, it is unclear whether there is an association between recurrent CV events and low APTT values and between bleeding and high APTT values... - Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparinS M Bates
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Arch Intern Med 161:385-91. 2001..We sought to identify an aPTT ratio that corresponds to therapeutic anti--factor Xa heparin levels for combinations of several reagents and coagulometers that are commonly used... - Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinaseJ A Anderson
Hamilton Civic Hospitals Research Centre and Department of Medicine, McMaster University, Hamilton, Ontario L8V 1C3, Canada
J Biol Chem 276:9755-61. 2001..These studies reveal that sLA-LMWH acts as a potent antithrombin-independent inhibitor of coagulation by attenuating intrinsic tenase and prothrombinase... - Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolismClive Kearon
McMaster University and the Henderson Research Centre, Hamilton, Ontario
JAMA 296:935-42. 2006..TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00182403... - Irbesartan in patients with atrial fibrillationSalim Yusuf
Population Health Research Institute, McMaster University, Hamilton, ON, Canada
N Engl J Med 364:928-38. 2011..The risk of cardiovascular events among patients with atrial fibrillation is high. We evaluated whether irbesartan, an angiotensin-receptor blocker, would reduce this risk... - Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factorC Kearon
McMaster University, Hamilton, Ontario, Canada
J Thromb Haemost 2:743-9. 2004..Retrospective analyses suggest that 1 month of anticoagulation is adequate for patients whose venous thromboembolic event was provoked by a transient risk factor... - Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover studyJ S Ginsberg
Department of Medicine, McMaster University, Hamilton, Ont
CMAJ 160:1303-6. 1999..This study was performed to determine whether intermittent compression therapy with an extremity pump benefits patients with this condition and, if so, whether the benefit is sustained... - A randomized trial comparing 5-mg and 10-mg warfarin loading dosesM A Crowther
Hamilton Civic Hospitals Research Centre, Ontario, Canada
Arch Intern Med 159:46-8. 1999.... - Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patientsM Sobieraj-Teague
Flinders Medical Centre, Bedford Park, SA, Australia Department of Medicine, McMaster University, Hamilton, ON, Canada
J Thromb Haemost 10:229-35. 2012..7% vs. 8.0%) and symptomatic VTE (0% vs. 2.7%), and the results were consistent in all subgroups examined. Conclusions: Venowave devices are effective in preventing VTE in high-risk neurosurgical patients... - Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testingC Kearon
McMaster University Clinic, Room 401, Henderson General Hospital, 711 Concession Street; Hamilton, Ontario L8V 1C3, Canada
Ann Intern Med 135:108-11. 2001..9% to 100%]). CONCLUSION: The combination of a low pretest probability of deep venous thrombosis and a negative result on a whole-blood D -dimer test rules out deep venous thrombosis in a large proportion of symptomatic outpatients... - Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort studyM A Crowther
Hamilton Civic Hospitals Research Centre, Henderson General Hospital, ON, Canada
Thromb Haemost 85:390-4. 2001..Our study also confirms that patients with idiopathic venous thromboembolism have a high risk of recurrence... - Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Shannon M Bates
Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
Chest 133:844S-886S. 2008.... - Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialAlexander G G Turpie
McMaster University, Hamilton, Ontario L8L 2X2, Canada
Lancet 373:1673-80. 2009..We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty... - An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patientsTheodore E Warkentin
McMaster University, The Henderson Research Centre, and the Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada
Arch Intern Med 163:2518-24. 2003..We sought to determine an improved definition of thrombocytopenia indicating HIT in postoperative orthopedic patients, including its impact on frequency and thrombotic risk of HIT... - Diagnosis and treatment of venous thromboembolismAgnes Y Y Lee
Department of Medicine, McMaster University, Hamilton Health Sciences, Henderson Site, 711 Concession Street, Hamilton, Ontario, L8V 1C3, Canada
Annu Rev Med 53:15-33. 2002..Aspects of thrombosis treatment that remain controversial include vena caval interruption and the indications for thrombolysis and surgical thromboembolectomy... - New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyJeffrey I Weitz
Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada
Chest 126:265S-286S. 2004.... - A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndromeMark A Crowther
Department of Medicine, McMaster University, Hamilton, Ont, Canada
N Engl J Med 349:1133-8. 2003..0. However, there are no prospective data to support this approach to thromboprophylaxis... - New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Jeffrey I Weitz
Henderson Research Center, McMaster University, 711 Concession Street, Hamilton, Ontario, Canada
Chest 133:234S-256S. 2008.... - Current anticoagulant therapy--unmet clinical needsJack Hirsh
Department of Medicine, Hamilton Civic Hospitals Research Centre, and McMaster University, Hamilton, Ontario, Canada
Thromb Res 109:S1-8. 2003..The mechanism of action and properties of these new anticoagulants and their potential to replace those in current use will be reviewed here... - Dabigatran versus warfarin in patients with atrial fibrillationStuart J Connolly
Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
N Engl J Med 361:1139-51. 2009..Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor... - Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trialShamir R Mehta
McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
Lancet 376:1233-43. 2010..We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI... - Prevention and treatment of postphlebitic syndrome: results of a 3-part studyJ S Ginsberg
Department of Medicine, McMaster University Medical Center, 1200 Main St W, HSC-3W11, Hamilton, Ontario, Canada L8N 3Z5
Arch Intern Med 161:2105-9. 2001..99). CONCLUSIONS: Most patients do not have PPS 1 year after proximal DVT, and do not require stockings. We failed to show a benefit of stockings in patients with PPS, but the small numbers preclude definitive conclusions... - American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?John W Eikelboom
Department of Medicine, McMaster University, Hamilton, ON, Canada
Chest 135:513-20. 2009.... - Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?Kevin H T Teoh
Department of Surgery, McMaster University, Hamilton, Ontario, Canada
J Thorac Cardiovasc Surg 128:211-9. 2004.... - In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulationLori Ann Linkins
Henderson Research Centre and McMaster University, 711 Concession Street, Hamilton, Ontario, Canada L8V 1C3
Thromb Res 107:241-4. 2002..The ACT and aPTT therefore cannot be used to monitor low-molecular weight heparin or fondaparinux, highlighting the need for a point-of-care anti-factor Xa assay... - Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic reviewMartin O'Donnell
Henderson Research Centre, Hamilton, Ontario, Canada
Arch Intern Med 163:1362-6. 2003.... - Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort studyTheodore E Warkentin
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
Chest 127:1857-61. 2005.... - Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Jack Hirsh
Hamilton Civic Hospitals, Hamilton, Ontario, Canada
Chest 133:110S-112S. 2008.... - Effects of CYP2C19 genotype on outcomes of clopidogrel treatmentGuillaume Pare
Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
N Engl J Med 363:1704-14. 2010.... - Platelet ADP-receptor antagonists for cardiovascular disease: past, present and futureNina C Raju
Thrombosis Service, Hamilton General Hospital, 237 Barton Street East, Hamilton, ON L8L2X2, Canada
Nat Clin Pract Cardiovasc Med 5:766-80. 2008..The nonthienopyridine P2Y(12) inhibitors AZD6140 and cangrelor are presently being evaluated in phase III, randomized, controlled trials... - New oral anticoagulants: not quite there yetGanesan Karthikeyan
Department of Medicine, McMaster University, Hamilton, ON, Canada
Pol Arch Med Wewn 119:53-8. 2009..In this review, we attempt to provide a balanced perspective on the relative merits and demerits of the new, orally active anticoagulants, and speculate on the future of these agents in clinical practice... - Reversal of the anti-platelet effects of aspirin and clopidogrelC Li
Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
J Thromb Haemost 10:521-8. 2012..Guidelines recommend stopping aspirin and clopidogrel 7 to 10 days before surgery to allow time for replacement of permanently inhibited platelets by newly released uninhibited platelets... - Effect of a preoperative intervention on preoperative and postoperative outcomes in low-risk patients awaiting elective coronary artery bypass graft surgery. A randomized, controlled trialH M Arthur
McMaster University, Faculty of Health Sciences and Hamilton Health Sciences Corporation, Ontario, Canada
Ann Intern Med 133:253-62. 2000..In publicly funded health care systems, a waiting period for such services as coronary artery bypass graft surgery (CABG) is common. The possibility of using the waiting period to improve patient outcomes should be investigated... - Developing a novel antithrombotic in the academic environmentJ Hirsh
Hamilton Civic Hospital Research Center and McMaster University, Hamilton, Ontario, Canada
Semin Hematol 38:4-11. 2001..Since their creation, Vascular Therapeutics and Osteokine have attracted major funding and developed several patentable compounds that show clinical and commercial promise... - Combined antiplatelet and anticoagulant therapy: clinical benefits and risksJ W Eikelboom
Thrombosis Service, Hamilton General Hospital, Hamilton, ON, Canada
J Thromb Haemost 5:255-63. 2007..Whether the benefits of triple therapy outweigh the risks in patients with atrial fibrillation and coronary stents requires evaluation in randomized trials... - Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Jack Hirsh
Hamilton Civic Hospitals, Hamilton, Ontario, Canada
Chest 133:71S-109S. 2008 - Monitoring unfractionated heparin with the aPTT: time for a fresh lookJohn W Eikelboom
Thrombosis Service, Hamilton General Hospital, Hamilton Health Sciences Corporation and McMaster University, Hamilton, Ontario, Canada
Thromb Haemost 96:547-52. 2006..However, currently available unfractionated heparin assays are much more expensive than the aPTT, are not widely available, and their validity has not been adequately assessed in clinical outcome studies... - Guidelines for anticoagulant use in acute coronary syndromesJohn Eikelboom
Thrombosis Service, Hamilton General Hospital, Hamilton, Ont, Canada, L8L 2X2
Lancet 371:1559-61. 2008 - Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Carlo Patrono
Catholic University School of Medicine, Largo F Vito 1, Rome, Italy
Chest 133:199S-233S. 2008.... - Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Jack Ansell
Department of Medicine, Boston University Medical Center, 88 East Newton Street, Boston, MA 02118, USA
Chest 133:160S-198S. 2008..Patient self-monitoring or self-management, however, is a choice made by patients and physicians that depends on many factors. We suggest that such therapeutic management be implemented where suitable (Grade 2B)... - Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular eventsJohn W Eikelboom
Department of Medicine, University of Western Australia, Thrombosis and Haemophilia Unit, Royal Perth Hospital, Perth, Australia
Circulation 105:1650-5. 2002..We studied whether aspirin resistance, defined as failure of suppression of thromboxane generation, increases the risk of cardiovascular events in a high-risk population... - Reflecting on eight editions of the American College of Chest Physicians antithrombotic guidelinesJack Hirsh
Chest 133:1293-5. 2008 - Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trialJohn A Cairns
University of British Columbia, Vancouver, British Columbia, Canada
Am Heart J 155:33-41. 2008.... - Is impaired renal function a contraindication to the use of low-molecular-weight heparin?Jeff Nagge
Toronto General Hospital, Eaton North Wing G 260, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4
Arch Intern Med 162:2605-9. 2002..50 mL/s) should be excluded from treatment with low-molecular-weight (LMW) heparin, or have anti-factor Xa heparin level monitoring performed... - Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparinRobert Raschke
Good Samaritan Regional Medical Center, 1111 East McDowell Road, Phoenix, Arizona 85006, USA
Ann Intern Med 138:720-3. 2003..Therapeutic ranges of 1.5 to 2.5 times the control value are subtherapeutic for most modern aPTT reagents... - Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee RegistryFrederick A Anderson
Center for Outcomes Research, Department of Surgery, University of Massachusetts Medical School, 365 Plantation Street, Suite 185, Worcester, MA, USA
Chest 124:349S-356S. 2003..During this same period, the proportion of patients receiving spinal/epidural anesthesia who were also administered anticoagulants as prophylaxis increased significantly... - Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgeryGary E Raskob
College of Public Health, Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, 801 NE Thirteenth Street, Room 139, Oklahoma City, OK 73104, USA
Chest 124:379S-385S. 2003.... - Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiologyCarlo Patrono
ESC Task Force on Antiplatelets, University of Rome La Sapienza, , Via di Grottarossa, 1035, 00189 Roma, Italy
Eur Heart J 25:166-81. 2004 - Randomized trial of warfarin nomogramsMark A Crowther
Ann Intern Med 140:490; author reply 491-2. 2004 - Establishing an optimal therapeutic range for coumarins: filling in the gapsJack Hirsh
Arch Intern Med 164:588-90. 2004 - The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyJack Ansell
Department of Medicine, Boston University Medical Center, 88 E Newton St, Boston, MA 02118, USA
Chest 126:204S-233S. 2004.... - Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyCarlo Patrono
University of Rome La Sapienza, Via di Grottarossa 1035, 00189 Rome, Italy
Chest 126:234S-264S. 2004.... - Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyShannon M Bates
McMaster University Medical Center, 1200 Main St West, Hamilton, ON L8N 325
Chest 126:627S-644S. 2004..In high-risk women with prosthetic heart valves, we suggest the addition of low-dose aspirin, 75 to 162 mg/d (Grade 2C)... - Anticoagulation for venous thromboembolismJohn W Eikelboom
BMJ 334:645. 2007 - Perioperative management of patients receiving oral anticoagulantsClive Kearon
Arch Intern Med 163:2532-3; author reply 2533. 2003 - Heparin resistance in acute coronary syndromesJonathan D Rich
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
J Thromb Thrombolysis 23:93-100. 2007..Direct thrombin inhibitors may offer an advantage in more predictable anticoagulation... - [Expert consensus document on the use of antiplatelet agents]Carlo Patrono
Rev Esp Cardiol 57:963-80. 2004 - American Heart Association/American College of Cardiology Foundation guide to warfarin therapyJack Hirsh
Circulation 107:1692-711. 2003 - American Heart Association/American College of Cardiology Foundation guide to warfarin therapyJack Hirsh
J Am Coll Cardiol 41:1633-52. 2003 - Electrical foot stimulation and implications for the prevention of venous thromboembolic diseaseRobert E Kaplan
Department of Pediatrics, State University of New York, Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York, USA
Thromb Haemost 88:200-4. 2002..A safe and convenient method for reducing venous stasis would be useful in patients while in hospital and after discharge during their rehabilitation...